Repligen Co. (NASDAQ:RGEN) is Brown Capital Management LLC’s 9th Largest Position

Brown Capital Management LLC grew its position in Repligen Co. (NASDAQ:RGEN) by 5.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,525,064 shares of the biotechnology company’s stock after purchasing an additional 83,416 shares during the period. Repligen comprises approximately 4.1% of Brown Capital Management LLC’s holdings, making the stock its 9th largest holding. Brown Capital Management LLC’s holdings in Repligen were worth $274,207,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in RGEN. Benjamin F. Edwards & Company Inc. grew its stake in Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares in the last quarter. Principal Securities Inc. acquired a new position in Repligen in the 4th quarter valued at approximately $48,000. Signaturefd LLC increased its stake in Repligen by 48.4% in the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 136 shares during the period. Picton Mahoney Asset Management purchased a new stake in Repligen in the 4th quarter worth approximately $90,000. Finally, Operose Advisors LLC acquired a new stake in shares of Repligen during the 3rd quarter valued at $99,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of research reports. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Finally, JPMorgan Chase & Co. lowered their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Repligen Stock Performance

RGEN opened at $142.87 on Thursday. The stock has a 50-day moving average of $162.47 and a 200-day moving average of $176.88. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a market cap of $7.98 billion, a PE ratio of 571.50, a price-to-earnings-growth ratio of 4.72 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter last year, the business earned $0.64 EPS. As a group, equities research analysts forecast that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.